Duchenne Muscular Dystrophy Clinical Trial
— TAMDMDOfficial title:
Tamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week Trial
Verified date | December 2022 |
Source | University Hospital, Basel, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A randomised, double blind, placebo controlled, 48-week clinical trial with a core population (group A) of 79 ambulant 6.5 to 12 years old Duchenne's muscular dystrophy (DMD) patients that are under stable standard treatment of care with glucocorticoids. Furthermore, the investigators plan to include 6-20 non-ambulant patients who do not receive glucocorticoids (as parallel group B), 10 to 16 years old, to obtain efficacy and safety data in a broader DMD population. All patients will receive 20 mg of tamoxifen (TAM) or placebo once daily during 48 weeks. An open label extension (OLE) trial for participants of the TAMDMD main study will be performed. All TAMDMD patients on TAM or placebo are offered to enter this OLE.
Status | Completed |
Enrollment | 93 |
Est. completion date | October 18, 2022 |
Est. primary completion date | July 25, 2022 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 78 Months to 16 Years |
Eligibility | Inclusion Criteria: Group A (ambulant patients) - Documented diagnosis of DMD by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e. absent or <5% of normal) on Western blot or immunostaining - Stable treatment with glucocorticoids >6 months (no significant change in dosage (>0.2mg/kg)) at screening; dosing adaptations according to weight change are allowed - Male gender - 6.5 to 12 years of age at time of screening - weight >20kg - ambulant patients - able to walk at least 350 meters in 6 minute walking distance test without assistance at screening - MFM D1 subdomain of the MFM scale >40% at screening - Ability to provide informed consent and to comply with study requirements - Patients harbouring a nonsense mutation treatable with the approved drug ataluren should be under stable ataluren treatment for at least 3 months or in case of nontolerance being off ataluren treatment for at least 3 months before screening Group B (non-ambulant patients) - Documented diagnosis of DMD by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e. absent or <5% of normal) on Western blot or immunostaining - Not using glucocorticoids for >6 months - Male gender - Non-ambulant patients (walking distance less than 10 meters) - 10 to 16 years of age at time of screening - Ability to provide informed consent and to comply with study requirements Open label extension - Recent participation and completion of TAMDMD study Exclusion Criteria: - Known individual hypersensitivity or allergy to tamoxifen or other ingredients/excipients of IMP - Female gender - Use of tamoxifen or testosterone within the last 3 months - Known or suspected malignancy - Other chronic disease or clinically relevant limitation of renal, liver or heart function - Known or suspected non-compliance - Any injury which may impact functional testing, e.g. upper or lower limb fracture - Planned or expected spinal fusion surgery during the study period (as judged by the Investigator; i.e. due to rapid progressing scoliosis), previous spinal fusion surgery is allowed if it took place more than 6 months prior to screening. - Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders of the participant/parents (as judged by the investigator) - Concomitant participation in any other interventional trial (and up to 3 months prior to screening) - Use of CYP2D6 inhibitors or of CYP3A4 inducers (apart from glucocorticoids), platelet aggregation inhibitors and coumarin-type anti-coagulants - Use of drugs metabolized by CYP2C9, such as phenprocoumon, phenytoin, warfarin, celecoxib, fluvastatin, ginko biloba, St. John's wort and sulfamethoxazol - Galactosemia (lack of galactose-1-phosphat-uridylyltransferase or UDP-galactose-4-epimerase or galactokinase; Fanconi-Bickel-syndrome); congenital lack of lactase; glucose-galactose malabsorption - Presence of one or more of the following eye disorders: cataract, retinopathia, optic neuropathy, alteration of the cornea - Presence of one or more of the following laboratory abnormalities: anaemia, thrombocytopenia, leukopenia, neutropenia or agranulocytosis Group A: - Glucocorticoid naïve patients - Start of glucocorticoid treatment or change in dosage <6 month prior to screening (dosing adaptations according to weight change are allowed) Group B: - Glucocorticoid treated patients or patients that stopped glucocorticoid treatment <6 month prior to screening - Assisted ventilation of any kind necessary |
Country | Name | City | State |
---|---|---|---|
France | Hôpitaux Raymond Poincaré | Garches | |
France | Hôpital de Hautepierre | Strasbourg | |
Germany | DRK Klinik Berlin Westend | Berlin | |
Germany | Universitätsklinikum Essen | Essen | |
Netherlands | Radboud umc | Nijmegen | |
Spain | Hospital Sant Joan de Déu. UB | Esplugues de Llobregat | Barcelona |
Spain | Hospital Universitario Virgen del Rocío | Sevilla | |
Switzerland | University Children's Hospital Basel | Basel | |
United Kingdom | Royal Hospital for Children | Glasgow | |
United Kingdom | The Leeds Teaching Hospitals NHS Trust | Leeds | |
United Kingdom | Alder Hey Children's Hospital | Liverpool |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland |
France, Germany, Netherlands, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient reported outcome measured by PARS III questionnaire | Personal Adjustment and Role Skills Scale (PARS-III) from baseline to week 48 under TAM treatment under TAM treatment compared to placebo. | Baseline to week 48 | |
Primary | Reduction of disease progression | To test if tamoxifen treatment, compared to placebo, reduces the progression of the disease in 6.5-12 years old ambulant DMD patients (Group A) by at least 50% (using the MFM D1 subscore as primary clinical endpoint). | Baseline to week 48 | |
Secondary | Muscle function measured by D2 MFM subscore | D2 MFM subscore from baseline to week 48 under TAM treatment compared to placebo. | Baseline to week 48 | |
Secondary | Muscle function measured by D3 MFM subscore | D3 MFM subscore from baseline to week 48 under TAM treatment compared to placebo. | Baseline to week 48 | |
Secondary | Muscle function measured by North Star Ambulatory Assessment | North Star Ambulatory Assessment from baseline to week 48 under TAM treatment compared to placebo. | Baseline to week 48 | |
Secondary | Muscle function measured by proximal upper limb function | Proximal upper limb function from baseline to week 48 under TAM treatment compared to placebo. | Baseline to week 48 | |
Secondary | Muscle function measured by 6 minute walking distance in meter | 6 minute walking distance in meter from baseline to week 48 under TAM treatment compared to placebo. | Baseline to week 48 | |
Secondary | Muscle function measured by 10 meter walking time in seconds | 10 meter walking time in seconds from baseline to week 48 under TAM treatment compared to placebo. | Baseline to week 48 | |
Secondary | Muscle function measured by time to rise from lying on the floor / supine up in seconds | time to rise from lying on the floor / supine up in seconds from baseline to week 48 under TAM treatment compared to placebo. | Baseline to week 48 | |
Secondary | Muscle force measured by quantitative muscle testing (using Myogrip) | Quantitative muscle testing (using Myogrip) from baseline to week 48 under TAM treatment compared to placebo. | Baseline to week 48 | |
Secondary | Muscle Degeneration measured by MRI | Quantitative muscle MRI including muscle fat fraction (MFF) and T2 times of thigh muscles visualised by MRI from baseline to week 48 under TAM treatment compared to placebo. | Baseline to week 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05575648 -
Dual Task in Duchenne Muscular Dystrophy
|
N/A | |
Terminated |
NCT03907072 -
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06450639 -
An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Active, not recruiting |
NCT04906460 -
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02500381 -
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 3 | |
Enrolling by invitation |
NCT05967351 -
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
|
Phase 3 | |
Recruiting |
NCT03067831 -
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT01834040 -
Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Completed |
NCT02246478 -
A Study of TAS-205 for Duchenne Muscular Dystrophy
|
Phase 1 | |
Active, not recruiting |
NCT01772043 -
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
|
N/A | |
Terminated |
NCT01168908 -
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT00758225 -
Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)
|
Phase 2 | |
Completed |
NCT03680365 -
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
|
||
Recruiting |
NCT03513367 -
The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
|
||
Recruiting |
NCT05712447 -
Duchenne Muscular Dystrophy Video Assessment Registry
|
||
Recruiting |
NCT01484678 -
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
|
||
Completed |
NCT03319030 -
Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
|
||
Terminated |
NCT01753804 -
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.
|
N/A | |
Completed |
NCT02530905 -
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
|
Phase 1 |